1. Introduction {#sec1}
===============

Familial Mediterranean Fever is an autosomal recessive inherited inflammatory disease \[[@B1]--[@B12]\] (however, it has been observed that a substantial number of patients with clinical FMF possess only one demonstrable*MEFV* mutation \[[@B2], [@B3]\]) that is principally seen in different countries \[[@B4]--[@B8]\]. However, patients from different ethnicities (such as Japan) are being increasingly recognized \[[@B9], [@B10]\], and the carrier frequency for*MEFV* genetic variants in the population in the Mediterranean basin is about 8% \[[@B11]\]. Most cases of FMF usually present with acute abdominal pain and fever \[[@B1], [@B12], [@B5]\], both of which are also the main causes of referral in the emergency department \[[@B13]\]. All these factors may help in medical treatment. Colchicine is the first line therapy \[[@B14]\], but in resistant cases (\<10% of patients) \[[@B15]\], it affects the responsiveness to Colchicine \[[@B16]\]; other anti-inflammatory drugs can be used for extra anti-inflammatory effect \[[@B17]\]. If FMF is not treated, it may be an etiologic factor for colonic LNH in children \[[@B18]\].*MEFV* gene is localized on 16p13.3 of chromosome 16 at position 13.3 which consists of 10 exons with 21600 bp \[[@B12], [@B19]\]. The disease is characterized by recurrent febrile episodes and inflammation in the form of sterile polyserositis. Amyloid protein involved in inflammatory amyloidosis was named AA (amyloid‐associated) protein and its circulating precursor was named SAA (serum amyloid‐associated). Amyloidosis of the AA type is the most severe complication of the disease. The gene responsible for FMF,*MEFV*, encodes a protein called pyrin or marenostrin and is expressed mainly in neutrophils \[[@B12], [@B19]\].

The definition of the*MEFV* gene has permitted genetic diagnosis of the disease. Nevertheless, as studies have unwrapped molecular data, problems have arisen with the clinical definitions of the disease \[[@B20]\]. FMF is caused by mutations in the*MEFV* missense SNPs (we were focusing on SNPs which are located in the coding region because it is much important in disease causing potential, which are responsible for amino acid residue substitutions resulting in functional diversity of proteins in humans) \[[@B20]\] coding for pyrin, which is a component of inflammasome functioning in inflammatory response and production of interleukin-1*β* (IL-1*β*). Recent studies have shown that pyrin recognizes bacterial modifications in Rho GTPases, which results in inflammasome activation and increase in IL-1*β*. Pyrin does not directly recognize Rho modification but probably is affected by Rho effector kinase, which is a downstream event in the actin cytoskeleton pathway \[[@B19], [@B21], [@B22]\].

The aim of this study was to identify the pathogenic SNPs in*MEFV* using in silico prediction software and to determine the structure, function, and regulation of their respective proteins. This is the first in silico analysis in*MEFV* gene to prioritize SNPs for further genetic mapping studies. The usage of in silico approach has strong impact on the identification of candidate SNPs since they are easy and less costly and can facilitate future genetic studies \[[@B23]\].

2. Method {#sec2}
=========

2.1. Data Mining {#sec2.1}
----------------

The data on human*MEFV* gene was collected from National Center for Biological Information (NCBI) website \[[@B24]\]. The SNP information (protein accession number and SNP ID) of the*MEFV* gene was retrieved from the NCBI dbSNP (http://www.ncbi.nlm.nih.gov/snp/) and the protein sequence was collected from Swiss Prot databases (http://expasy.org/) \[[@B25]\].

2.2. SIFT {#sec2.2}
---------

SIFT is a sequence homology-based tool \[[@B26]\] that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution in a protein will have a phenotypic effect. It considers the position at which the change occurred and the type of amino acid change. Given a protein sequence, SIFT chooses related proteins and obtains an alignment of these proteins with the query. Based on the amino acids appearing at each position in the alignment, SIFT calculates the probability that an amino acid at a position is tolerated conditional on the most frequent amino acid being tolerated. If this normalized value is less than a cutoff, the substitution is predicted to be deleterious. SIFT scores \<0.05 are predicted by the algorithm to be intolerant or deleterious amino acid substitutions, whereas scores \>0.05 are considered tolerant. It is available at (http://sift.bii.a-star.edu.sg/).

2.3. PolyPhen-2 {#sec2.3}
---------------

It is a software tool \[[@B27]\] to predict possible impact of an amino acid substitution on both structure and function of a human protein by analysis of multiple sequence alignment and protein 3D structure; in addition, it calculates position-specific independent count scores (PSIC) for each of the two variants and then calculates the PSIC scores difference between the two variants. The higher a PSIC score difference is, the higher the functional impact a particular amino acid substitution is likely to have. Prediction outcomes could be classified as probably damaging, possibly damaging or benign according to the value of PSIC as it ranges from (0_1); values closer to zero were considered benign while values closer to 1 were considered probably damaging and also it can be indicated by a vertical black marker inside a color gradient bar, where green is benign and red is damaging. nsSNPs that is predicted to be intolerant by SIFT has been submitted to PolyPhen as protein sequence in FASTA format obtained from UniproktB/Expasy after submitting the relevant ensemble protein (ESNP) there, and then we entered position of mutation, native amino acid, and the new substituent for both structural and functional predictions. PolyPhen version 2.2.2 is available at [http://genetics.bwh.harvard.edu/pph2/index.shtml.](http://genetics.bwh.harvard.edu/pph2/index.shtml)

2.4. Provean {#sec2.4}
------------

Provean is a software tool \[[@B28]\] which predicts whether an amino acid substitution or indel has an impact on the biological function of a protein. It is useful for filtering sequence variants to identify nonsynonymous or indel variants that are predicted to be functionally important. It is available at (https://rostlab.org/services/snap2web/).

2.5. SNAP2 {#sec2.5}
----------

Functional effects of mutations are predicted with SNAP2 \[[@B29]\]. SNAP2 is a trained classifier that is based on a machine learning device called "neural network". It distinguishes between effect and neutral variants/nonsynonymous SNPs by taking a variety of sequence and variant features into account. The most important input signal for the prediction is the evolutionary information taken from an automatically generated multiple sequence alignment. Also structural features such as predicted secondary structure and solvent accessibility are considered. If available also annotation (i.e., known functional residues, pattern, regions) of the sequence or close homologs are pulled in. In a cross-validation over 100,000 experimentally annotated variants, SNAP2 reached sustained two-state accuracy (effect/neutral) of 82% (at an AUC of 0.9). In our hands this constitutes an important and significant improvement over other methods. It is available at (https://rostlab.org/services/snap2web/).

2.6. PHD-SNP {#sec2.6}
------------

An online Support Vector Machine (SVM) based classifier is optimized to predict if a given single point protein mutation can be classified as disease related or as a neutral polymorphism. It is available at (http://snps.biofold.org/phd-snp/phd-snp.html).

2.7. SNP&Go {#sec2.7}
-----------

SNPs&GO is an algorithm developed in the Laboratory of Biocomputing at the University of Bologna directed by Prof. Rita Casadio. SNPs&GO is an accurate method that, starting from a protein sequence, can predict whether a variation is disease related or not by exploiting the corresponding protein functional annotation. SNPs&GO collects in unique framework information derived from protein sequence, evolutionary information, and function as encoded in the Gene Ontology terms and outperforms other available predictive methods \[[@B30]\]. It is available at (http://snps.biofold.org/snps-and-go/snps-and-go.html).

2.8. P-Mut {#sec2.8}
----------

P-MuT, a web-based tool \[[@B31]\] for the annotation of pathological variants on proteins, allows the fast and accurate prediction (approximately 80% success rate in humans) of the pathological character of single point amino acidic mutations based on the use of neural networks. It is available at (http://mmb.irbbarcelona.org/PMut).

2.9. I-Mutant 3.0 {#sec2.9}
-----------------

I-Mutant 3.0 is a neural network based tool \[[@B32]\] for the routine analysis of protein stability and alterations by taking into account the single-site mutations. The FASTA sequence of protein retrieved from UniProt is used as an input to predict the mutational effect on protein stability. It is available at ([http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/](http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi)[I-Mutant3.0.cgi](http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi)).

2.10. Modeling nsSNP Locations on Protein Structure {#sec2.10}
---------------------------------------------------

Project hope is a new online web-server to search protein 3D structures (if available) by collecting structural information from a series of sources, including calculations on the 3D coordinates of the protein, sequence annotations from the UniProt database, and predictions by DAS services. Protein sequences were submitted to project hope server in order to analyze the structural and conformational variations that have resulted from single amino acid substitution corresponding to single nucleotide substitution. It is available at (http://www.cmbi.ru.nl/hope).

2.11. GeneMANIA {#sec2.11}
---------------

We submitted genes and selected from a list of data sets that they wish to query. GeneMANIA\'s \[[@B33]\] approach is to know protein function prediction integrating multiple genomics and proteomics data sources to make inferences about the function of unknown proteins. It is available at (http://www.genemania.org/).

3. Results and Discussion {#sec3}
=========================

3.1. Result {#sec3.1}
-----------

See Tables [1](#tab1){ref-type="table"}[](#tab2){ref-type="table"}[](#tab3){ref-type="table"}[](#tab4){ref-type="table"}--[5](#tab5){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}.

4. Discussion {#sec4}
=============

23 novel mutations have been found (see [Table 3](#tab3){ref-type="table"}) which affected the stability and function of the*MEFV* gene using bioinformatics tools. The methods used were based on different aspects and parameters describing the pathogenicity and provided clues on the molecular level about the effect of mutations. It was not easy to predict the pathogenic effect of SNPs using single method. Therefore, multiple methods were used to compare and rely on the results predicted. In this study we used different in silico prediction algorithms: SIFT, PolyPhen-2, Provean, SNAP2, SNP&GO, PHD-SNP, P-MuT, and I-Mutant 3.0 (see [Figure 1](#fig1){ref-type="fig"}).

This study identified the total number of nsSNP in Homo sapiens located in coding region of*MEFV* gene, which were investigated in dbSNP/NCBI Database \[[@B24]\]. Out of 2369, there are 856 nsSNPs (missense mutations) submitted to SIFT server, PolyPhen-2 server, Provean sever, and SNAP2, respectively, and 392 SNPs were predicted to be deleterious in SIFT server. In PolyPhen-2 server, the result showed that 453 were found to be damaging (147 possibly damaging and 306 probably damaging showing deleterious). In Provean server our result showed that 244 SNPs were predicted to be deleterious. While in SNAP2 server the result showed that 566 SNPs were predicted to have effect. The differences in prediction capabilities refer to the fact that every prediction algorithm uses different sets of sequences and alignments. In [Table 2](#tab2){ref-type="table"} we submitted four positive results from SIFT, PolyPhen-2, Provean, and SNAP2 (see [Table 1](#tab1){ref-type="table"}) to observe the disease causing one by SNP&GO, PHD-SNP, and P-Mut servers.

In SNP&GO, PHD-SNP and P-Mut softwares were used to predict the association of SNPs with disease. According to SNP&GO, PHD-SNP and P-Mut (70, 91 and 58 SNPs respectively) were found to be disease-related SNPs. We selected the triple disease-related SNPs only in 3 softwares for further analysis by I-Mutant 3.0, [Table 3](#tab3){ref-type="table"}. I-Mutant result revealed that the protein stability decreased which destabilizes the amino acid interaction (S749Y, F743S, Y741C, F731V, I720T, L709R, V691G, W689R, G668R, V659F, F636C, H407Q, H407R, H404R, C398Y, H378Q, H378Y, and L86P). C375R, C395F, C395R, C395Y, and R461W were found to increase the protein stability (see [Table 3](#tab3){ref-type="table"}).

BioEdit software was used to align 10 amino acid sequences of MEFV demonstrating that the residues predicted to be mutated in our band (indicated by red arrow) are evolutionarily conserved across species (see [Figure 2](#fig2){ref-type="fig"}). While Project HOPE software was used to submit the 23 most deleterious and damaging nsSNPs (see Figures [3](#fig3){ref-type="fig"}[](#fig4){ref-type="fig"}[](#fig5){ref-type="fig"}[](#fig6){ref-type="fig"}[](#fig7){ref-type="fig"}[](#fig8){ref-type="fig"}[](#fig9){ref-type="fig"}[](#fig10){ref-type="fig"}[](#fig11){ref-type="fig"}[](#fig12){ref-type="fig"}[](#fig13){ref-type="fig"}[](#fig14){ref-type="fig"}[](#fig15){ref-type="fig"}[](#fig16){ref-type="fig"}[](#fig17){ref-type="fig"}[](#fig18){ref-type="fig"}[](#fig19){ref-type="fig"}[](#fig20){ref-type="fig"}[](#fig21){ref-type="fig"}[](#fig22){ref-type="fig"}[](#fig23){ref-type="fig"}[](#fig24){ref-type="fig"}--[25](#fig25){ref-type="fig"}), L86P: Proline (the mutant residue) is smaller than Leucine (the wild-type residue); this might lead to loss of interactions. The wild-type and mutant amino acids differ in size. The mutation is located within a domain, annotated in UniProt as Pyrin. The mutation introduces an amino acid with different properties, which can disturb this domain and abolish its function. The wild-type residue is located in a region annotated in UniProt to form an *α*-helix. Proline disrupts an *α*-helix when not located at one of the first 3 positions of that helix. In case of the mutation at hand, the helix will be disturbed and this can have severe effects on the structure of the protein.

GeneMANIA revealed that*MEFV* has many vital functions: chemokine production, inflammatory response, interleukin-1 beta production, interleukin-1 production, intracellular receptor signaling pathway, nucleotide-binding domain, Leucine rich repeat containing receptor signaling pathway, positive regulation of cysteine-type endopeptidase activity, positive regulation of endopeptidase activity, positive regulation of peptidase activity, regulation of chemokine production, regulation of cysteine-type endopeptidase activity, regulation of endopeptidase activity, regulation of interleukin-1 beta production, regulation of interleukin-1 production, and regulation of peptidase activity. The genes coexpressed with, sharing similar protein domain, or participated to achieve similar function were shown in (see [Figure 26](#fig26){ref-type="fig"}) Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}.

In this study we also retrieved all these SNPs as untested (V659F, L709R, F743S, S749Y). We found it to be all damaging. Our study is the first in silico analysis of*MEFV* gene which was based on functional analysis while all previous studies \[[@B35], [@B36]\] were based on frequency. This study revealed that 23 novel pathological mutations have a potential functional impact and may thus be used as diagnostic markers for Mediterranean basin populations.

5. Conclusion {#sec5}
=============

In this work the influence of functional SNPs in the*MEFV* gene was investigated through various computational methods, which determined that S749Y, F743S, Y741C, F731V, I720T, L709R, V691G, W689R, G668R, V659F, F636C, R461W, H407Q,, H407R, H404R, C398Y, C395Y, C395F, C395R, H378Q, H378Y, C375R, and L86P are new SNPs having a potential functional impact and can thus be used as diagnostic markers. They constitute possible candidates for further genetic epidemiological studies with a special consideration of the large heterogeneity of*MEFV* SNPs among the different populations.
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![Diagrammatic representation of*MEFV* gene in silico work flow.](ABI2019-1651587.001){#fig1}

![Alignments of 10 amino acid sequences of*MEFV* demonstrating that the residues predicted to be mutated in our band (indicated by red arrow) are evolutionarily conserved across species. Sequences Alignment was done by BioEdit (v7.2.5).](ABI2019-1651587.002){#fig2}

![(L86P): change in the amino acid Leucine (green box) into Proline (red box) at position 86.](ABI2019-1651587.003){#fig3}

![(C375R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 375.](ABI2019-1651587.004){#fig4}

![(H378Y): change in the amino acid Histidine (green box) into Tyrosine (red box) at position 378.](ABI2019-1651587.005){#fig5}

![(H378Q): change in the amino acid Histidine (green box) into Glutamine (red box) at position 378.](ABI2019-1651587.006){#fig6}

![(C395R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 395.](ABI2019-1651587.007){#fig7}

![(C395F): change in the amino acid Cysteine (green box) into Phenylalanine (red box) at position 395.](ABI2019-1651587.008){#fig8}

![(C395Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 395.](ABI2019-1651587.009){#fig9}

![(C398Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 398.](ABI2019-1651587.010){#fig10}

![(H404R): change in the amino acid Histidine (green box) into Arginine (red box) at position 404.](ABI2019-1651587.011){#fig11}

![(H407R): change in the amino acid Histidine (green box) into Arginine (red box) at position 407.](ABI2019-1651587.012){#fig12}

![(H407Q): change in the amino acid Histidine (green box) into Glutamine (red box) at position 407.](ABI2019-1651587.013){#fig13}

![(R461W): change in the amino acid Arginine (green box) into Tryptophan (red box) at position 461.](ABI2019-1651587.014){#fig14}

![(F636C): change in the amino acid Phenylalanine (green box) into Cysteine (red box) at position 636.](ABI2019-1651587.015){#fig15}

![(V659F): change in the amino acid Valine (green box) into Phenylalanine (red box) at position 636.](ABI2019-1651587.016){#fig16}

![(G668R): change in the amino acid Glycine (green box) into Arginine (red box) at position 668.](ABI2019-1651587.017){#fig17}

![(W689R): change in the amino acid Tryptophan (green box) into Arginine (red box) at position 689.](ABI2019-1651587.018){#fig18}

![(V691G): change in the amino acid Valine (green box) into Glycine (red box) at position 691.](ABI2019-1651587.019){#fig19}

![(L709R): change in the amino acid Leucine (green box) into Arginine (red box) at position 709.](ABI2019-1651587.020){#fig20}

![(I720T): change in the amino acid Isoleucine (green box) into Threonine (red box) at position 720.](ABI2019-1651587.021){#fig21}

![(F731V): change in the amino acid Phenylalanine (green box) into Valine (red box) at position 731.](ABI2019-1651587.022){#fig22}

![(Y741C): change in the amino acid Tyrosine (green box) into Cysteine (red box) at position 731.](ABI2019-1651587.023){#fig23}

![(F743S): change in the amino acid Phenylalanine (green box) into Serine (red box) at position 743.](ABI2019-1651587.024){#fig24}

![(S749Y): change in the amino acid Serine (green box) into Tyrosine (red box) at position 749.](ABI2019-1651587.025){#fig25}

![Interaction between*MEFV* and its related genes.](ABI2019-1651587.026){#fig26}

###### 

Damaging or deleterious effect nsSNPs associated variations predicted by various softwares.

  *Amino Acid Change*   *SIFT*     *Polyphen*   *PROVEAN*           *SNAP2*                                    
  --------------------- ---------- ------------ ------------------- --------- --------- ------------- -------- ----
  S749Y                 DAMAGING   0            PROBABLY DAMAGING   1.000     -3.116    Deleterious   effect   64
  F743S                 DAMAGING   0            PROBABLY DAMAGING   1.000     -5.563    Deleterious   effect   68
  Y741C                 DAMAGING   0            PROBABLY DAMAGING   1.000     -6.035    Deleterious   effect   77
  F731V                 DAMAGING   0            PROBABLY DAMAGING   1.000     -5.159    Deleterious   effect   81
  I720T                 DAMAGING   0            PROBABLY DAMAGING   1.000     -3.639    Deleterious   effect   58
  L709R                 DAMAGING   0            PROBABLY DAMAGING   1.000     -4.311    Deleterious   effect   77
  V691G                 DAMAGING   0            PROBABLY DAMAGING   1.000     -4.667    Deleterious   effect   66
  W689R                 DAMAGING   0            PROBABLY DAMAGING   1.000     -10.132   Deleterious   effect   89
  G668R                 DAMAGING   0            PROBABLY DAMAGING   1.000     -6.287    Deleterious   effect   92
  V659F                 DAMAGING   0            PROBABLY DAMAGING   1.000     -3.811    Deleterious   effect   64
  F636C                 DAMAGING   0            PROBABLY DAMAGING   1.000     -6.49     Deleterious   effect   79
  R461W                 DAMAGING   0            PROBABLY DAMAGING   1.000     -5.456    Deleterious   effect   68
  H407Q                 DAMAGING   0            PROBABLY DAMAGING   1.000     -7.335    Deleterious   effect   41
  H407R                 DAMAGING   0            PROBABLY DAMAGING   1.000     -7.332    Deleterious   effect   51
  H404R                 DAMAGING   0            PROBABLY DAMAGING   1.000     -7.349    Deleterious   effect   75
  C398Y                 DAMAGING   0            PROBABLY DAMAGING   1.000     -10.314   Deleterious   effect   51
  C395Y                 DAMAGING   0            PROBABLY DAMAGING   1.000     -10.262   Deleterious   effect   19
  C395F                 DAMAGING   0            PROBABLY DAMAGING   1.000     -10.315   Deleterious   effect   27
  C395R                 DAMAGING   0            PROBABLY DAMAGING   1.000     -11.074   Deleterious   effect   27
  H378Q                 DAMAGING   0            PROBABLY DAMAGING   1.000     -5.886    Deleterious   effect   38
  H378Y                 DAMAGING   0            PROBABLY DAMAGING   1.000     -4.884    Deleterious   effect   45
  C375R                 DAMAGING   0            PROBABLY DAMAGING   1.000     -8.429    Deleterious   effect   66
  L86P                  DAMAGING   0            PROBABLY DAMAGING   1.000     -4.1      Deleterious   effect   19

###### 

Disease effect nsSNPs associated variations predicted by various softwares.

  -----------------------------------------------------------------------------------------------
  *Amino Acid Change*   SNP&GO    PHD-SNP   P-Mut\                                      
  --------------------- --------- --------- -------- --------- --- ------- ------------ ---------
  S749Y                 Disease   1         0.573    Disease   3   0.649   0.67 (85%)   Disease

  F743S                 Disease   2         0.617    Disease   4   0.696   0.82 (90%)   Disease

  Y741C                 Disease   6         0.797    Disease   7   0.869   0.61 (83%)   Disease

  F731V                 Disease   6         0.79     Disease   8   0.899   0.93 (94%)   Disease

  I720T                 Disease   6         0.811    Disease   5   0.769   0.81 (89%)   Disease

  L709R                 Disease   3         0.672    Disease   4   0.695   0.66 (85%)   Disease

  V691G                 Disease   1         0.55     Disease   3   0.675   0.92 (93%)   Disease

  W689R                 Disease   7         0.841    Disease   8   0.924   0.93 (94%)   Disease

  G668R                 Disease   6         0.778    Disease   7   0.84    0.93 (94%)   Disease

  V659F                 Disease   6         0.805    Disease   7   0.84    0.82 (90%)   Disease

  F636C                 Disease   6         0.809    Disease   7   0.86    0.60 (82%)   Disease

  R461W                 Disease   3         0.644    Disease   1   0.572   0.63 (84%)   Disease

  H407Q                 Disease   6         0.788    Disease   4   0.705   0.79 (89%)   Disease

  H407R                 Disease   5         0.769    Disease   3   0.673   0.86 (91%)   Disease

  H404R                 Disease   5         0.744    Disease   5   0.734   0.80 (89%)   Disease

  C398Y                 Disease   7         0.864    Disease   8   0.912   0.86 (91%)   Disease

  C395Y                 Disease   7         0.864    Disease   8   0.912   0.91 (93%)   Disease

  C395F                 Disease   7         0.859    Disease   8   0.914   0.92 (94%)   Disease

  C395R                 Disease   7         0.842    Disease   8   0.892   0.92 (94%)   Disease

  H378Q                 Disease   4         0.714    Disease   4   0.698   0.88 (92%)   Disease

  H378Y                 Disease   5         0.732    Disease   5   0.728   0.80 (89%)   Disease

  C375R                 Disease   6         0.784    Disease   6   0.822   0.92 (94%)   Disease

  L86P                  Disease   5         0.729    Disease   6   0.801   0.51 (79%)   Disease
  -----------------------------------------------------------------------------------------------

###### 

Stability analysis predicted by I-Mutant version 3.0 (also show the 23 novel mutations).

  *Amino Acid Change*   SVM2 Prediction Effect   RI   DDG Value Prediction
  --------------------- ------------------------ ---- ----------------------
  S749Y                 Decrease                 0    -0.2
  F743S                 Decrease                 6    -1.16
  Y741C                 Decrease                 8    -2.5
  F731V                 Decrease                 6    -1.52
  I720T                 Decrease                 4    -0.92
  L709R                 Decrease                 3    -0.56
  V691G                 Decrease                 7    -1.25
  W689R                 Decrease                 7    -0.73
  G668R                 Decrease                 4    -0.37
  V659F                 Decrease                 2    -0.19
  F636C                 Decrease                 8    -1.28
  R461W                 Increase                 1    -0.01
  H407Q                 Decrease                 8    -1.48
  H407R                 Decrease                 5    -1.1
  H404R                 Decrease                 1    -0.06
  C398Y                 Decrease                 2    -0.09
  C395Y                 Increase                 4    0.26
  C395F                 Increase                 1    0.04
  C395R                 Increase                 4    0.13
  H378Q                 Decrease                 4    -0.68
  H378Y                 Decrease                 3    -0.26
  C375R                 Increase                 2    -0.01
  L86P                  Decrease                 2    -0.56

###### 

The *MEFV* gene functions and its appearance in network and genome.

  Function                                                                                    FDR        Genes in network   Genes in genome
  ------------------------------------------------------------------------------------------- ---------- ------------------ -----------------
  nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway        1.42E-07   6                  47
  regulation of interleukin-1 beta production                                                 0.000129   4                  26
  interleukin-1 beta production                                                               0.000129   4                  30
  regulation of interleukin-1 production                                                      0.000129   4                  30
  interleukin-1 production                                                                    0.000196   4                  35
  intracellular receptor signaling pathway                                                    0.000201   6                  207
  positive regulation of cysteine-type endopeptidase activity                                 0.010438   4                  101
  positive regulation of endopeptidase activity                                               0.010663   4                  105
  positive regulation of peptidase activity                                                   0.011      4                  109
  inflammatory response                                                                       0.018246   5                  283
  regulation of chemokine production                                                          0.018246   3                  39
  chemokine production                                                                        0.022338   3                  44
  regulation of cysteine-type endopeptidase activity                                          0.033238   4                  160
  tumor necrosis factor production                                                            0.033238   3                  54
  regulation of tumor necrosis factor production                                              0.033238   3                  54
  tumor necrosis factor superfamily cytokine production                                       0.0407     3                  59
  regulation of I-kappaB kinase/NF-kappaB signaling                                           0.046902   4                  185
  I-kappaB kinase/NF-kappaB signaling                                                         0.057722   4                  198
  positive regulation of cytokine production                                                  0.065004   4                  207
  positive regulation of cysteine-type endopeptidase activity involved in apoptotic process   0.099763   3                  93
  positive regulation of interleukin-1 beta secretion                                         0.099763   2                  15
  defense response to Gram-negative bacterium                                                 0.099763   2                  16
  cysteine-type endopeptidase activator activity involved in apoptotic process                0.099763   2                  17
  regulation of endopeptidase activity                                                        0.099763   4                  251
  glycosaminoglycan binding                                                                   0.099763   3                  88
  regulation of extrinsic apoptotic signaling pathway                                         0.099763   3                  92
  regulation of peptidase activity                                                            0.099763   4                  258
  positive regulation of interleukin-1 secretion                                              0.099763   2                  16
  regulation of interleukin-1 beta secretion                                                  0.099763   2                  17

*∗FDR*: false discovery rate is greater than or equal to the probability that this is a false positive.

###### 

The gene coexpression, shared domain, and interaction with *MEFV* gene network.

  Gene 1     Gene 2     Weight     Network group
  ---------- ---------- ---------- ------------------------
  PF4        CEBPB      0.01083    Co-expression
  NLRP14     MEFV       0.014663   Co-expression
  EPX        PADI4      0.01094    Co-expression
  CASP1      PYCARD     0.012291   Co-expression
  TINAGL1    MEFV       0.021529   Co-expression
  ZNF747     MEFV       0.032075   Co-expression
  ZNF747     TINAGL1    0.01915    Co-expression
  EPX        MEFV       0.019982   Co-expression
  EPX        ZNF747     0.01848    Co-expression
  MRPL44     MEFV       0.02576    Co-expression
  RPL27A     MEFV       0.023047   Co-expression
  TCTN2      MEFV       0.02049    Co-expression
  TCTN2      ZNF747     0.021219   Co-expression
  TCTN2      RPL27A     0.019574   Co-expression
  ZNF528     RPL27A     0.021843   Co-expression
  ZNF528     TCTN2      0.020287   Co-expression
  PF4        TINAGL1    0.018596   Co-expression
  PF4        EPX        0.016477   Co-expression
  CASP1      PYCARD     0.005924   Co-expression
  NLRP3      CEBPB      0.01342    Co-expression
  CASP1      PYCARD     0.005896   Co-expression
  AZU1       MEFV       0.01109    Co-expression
  MAP1LC3C   NLRP14     0.011062   Co-expression
  PADI4      MEFV       0.003094   Co-expression
  AZU1       MEFV       0.003152   Co-expression
  AZU1       PADI4      0.004853   Co-expression
  ZNF747     MEFV       0.004908   Co-expression
  PADI4      MEFV       0.023362   Co-expression
  AZU1       MEFV       0.012616   Co-expression
  AZU1       PADI4      0.014322   Co-expression
  NLRP14     MEFV       0.01623    Co-expression
  EPX        PADI4      0.01024    Co-expression
  EPX        AZU1       0.007038   Co-expression
  ZNF528     MEFV       0.039375   Co-expression
  PF4        MEFV       0.017902   Co-expression
  PF4        AZU1       0.012247   Co-expression
  PF4        EPX        0.007715   Co-expression
  TINAGL1    MEFV       0.027084   Co-expression
  MRPL44     MEFV       0.011927   Co-expression
  TCTN2      MEFV       0.014192   Co-expression
  TCTN2      TINAGL1    0.014867   Co-expression
  TCTN2      ZNF747     0.010889   Co-expression
  TCTN2      MAP1LC3C   0.006994   Co-expression
  TCTN2      MRPL44     0.010528   Co-expression
  ZNF528     TCTN2      0.012167   Co-expression
  RPL27A     MEFV       0.016846   Co-expression
  TCTN2      RPL27A     0.018021   Co-expression
  CASP1      PSTPIP1    0.009518   Co-expression
  EPX        AZU1       0.01909    Co-localization
  PADI4      MEFV       0.012301   Co-localization
  PADI4      PSTPIP1    0.008748   Co-localization
  AZU1       MEFV       0.011852   Co-localization
  AZU1       PSTPIP1    0.008052   Co-localization
  AZU1       PADI4      0.006025   Co-localization
  EPX        MEFV       0.011933   Co-localization
  EPX        PSTPIP1    0.008374   Co-localization
  EPX        PADI4      0.006323   Co-localization
  EPX        AZU1       0.006061   Co-localization
  FBXO9      MEFV       0.022287   Co-localization
  FBXO9      PADI4      0.009957   Co-localization
  FBXO9      AZU1       0.009656   Co-localization
  FBXO9      EPX        0.009948   Co-localization
  PF4        MEFV       0.012063   Co-localization
  PF4        PSTPIP1    0.007583   Co-localization
  PF4        PADI4      0.005603   Co-localization
  PF4        AZU1       0.005356   Co-localization
  PF4        EPX        0.005651   Co-localization
  PF4        FBXO9      0.009449   Co-localization
  CEBPB      MEFV       0.159581   Pathway
  RELA       MEFV       0.078321   Pathway
  PSTPIP1    MEFV       0.953023   Pathway
  PYCARD     MEFV       0.037199   Pathway
  CASP1      PYCARD     0.037199   Pathway
  CASP1      MEFV       0.469715   Physical Interactions
  NLRP3      PYCARD     0.570819   Physical Interactions
  PYCARD     MEFV       0.03673    Physical Interactions
  PYCARD     PSTPIP1    0.028273   Physical Interactions
  CASP1      PYCARD     0.017772   Physical Interactions
  CASP1      CEBPB      0.010941   Physical Interactions
  RELA       CEBPB      0.00247    Physical Interactions
  COG5       MEFV       0.211887   Physical Interactions
  NLRP3      MEFV       0.111467   Physical Interactions
  MAP1LC3C   MEFV       0.104412   Physical Interactions
  PYCARD     MEFV       0.292858   Physical Interactions
  NLRP3      PYCARD     0.189095   Physical Interactions
  PSTPIP1    MEFV       0.260595   Physical Interactions
  PYCARD     MEFV       0.204673   Physical Interactions
  CASP1      PYCARD     0.042335   Physical Interactions
  RELA       CEBPB      0.007591   Physical Interactions
  COG5       MEFV       0.387501   Physical Interactions
  NLRP3      PYCARD     0.304828   Physical Interactions
  NLRP3      PYCARD     1          Predicted
  PYCARD     MEFV       0.455503   Predicted
  CASP1      PYCARD     0.043769   Predicted
  RELA       CEBPB      0.024601   Predicted
  NLRP3      PYCARD     0.25852    Predicted
  CASP1      CEBPB      0.445416   Predicted
  CASP1      CEBPB      0.707107   Predicted
  PYCARD     MEFV       0.00952    Shared protein domains
  CASP1      PYCARD     0.013543   Shared protein domains
  NLRP3      MEFV       0.009339   Shared protein domains
  NLRP3      PYCARD     0.018527   Shared protein domains
  NLRP14     MEFV       0.009512   Shared protein domains
  NLRP14     PYCARD     0.018871   Shared protein domains
  NLRP14     NLRP3      0.036989   Shared protein domains
  ZNF528     ZNF747     0.002699   Shared protein domains
  PYCARD     MEFV       0.011528   Shared protein domains
  CASP1      PYCARD     0.031451   Shared protein domains
  NLRP3      MEFV       0.009427   Shared protein domains
  NLRP3      PYCARD     0.015448   Shared protein domains
  NLRP14     MEFV       0.009815   Shared protein domains
  NLRP14     PYCARD     0.016085   Shared protein domains
  NLRP14     NLRP3      0.019774   Shared protein domains
  ZNF528     ZNF747     0.002759   Shared protein domains

[^1]: Academic Editor: Nurit Haspel
